The treatment of patients with asthma and comorbidity.

G. V. Yeryomenko, T. V. Bezditko

Abstract


The increa­sing prevalence of asthma (A) and diabetes mellitus type 2 (DM2T) necessitates administration of the adequate antia­sthmatic long-term basic therapy with consideration of comorbid states. The purpose consisted in revealing the therapeutic potential of Tiotropium bromide (TB) and L-arginine (Tivortine) in patients having uncontrolled moderately severe asthma in combination with DM2T (A+DM2T). Forty seven A+DM2T patients underwent an in-depth study before and after their treatment. They were divided into 2 groups: treatment (group 1, n=28) and comparison (group 2, n=19). Both groups received the standard 2-component therapy: budesonide/formoterol fumarate dihydrate – 160/4.5µg by 2 breaths twice a day and metformin at a dose of 500 mg twice a day. The complex of their basic therapy for group 1 additionally included TB (18 µg a day) and arginine hydrochloride preparation (Tivortine® aspartate, Yuriya-Farm) orally by 15 ml twice a day during 3 months (90 days). The patients were followed up 3 months and one year later. Their general condition demonstrated positive dynamics in both groups, the number of exacerbations in group 1 reducing by a factor of 4. The complex use of L-arginine and TB preparations against a background of the basic therapy in A+DM2T patients produced a better control over the disease, a more rapid elimination of obstruction manifestations, achievement and prolongation of the clinical spirographic remission, an improvement of the quality of life, correction of disturbances in haemocoagulation, fibrinolysis and the functional state of endothelium.


Keywords


asthma; diabetes mellitus type 2; MCP-1; MMP-9; von Willebrand factor; L-arginine; Tiotropium bromide

Full Text:

PDF

References


Barkagan ZS, Mоmоt АP. [Diagnosis and Con­trolled Therapy of Homeostatic Disorders]. Moskva, Nʹiu­diamed; 2008. Russian.

Vertkin AL, Hovasova NO. [Comorbidity is a new pathology. The technology of its prevention and treat­ment]. The Archives of Internal Medicine. 2013;4:68-72. Russian.

Katerenchuk IP. [Optimization of the correction of endothelial dysfunction in patients with metabolic syndrome in the practice of a family doctor]. Lіki Ukraїni. 2014;7/8:43-46. Ukrainian.

Koval'ovaOM, Gorbach TV, Demydenko GV. [Diagnosis of endothelial function, assessment of vaso­active nitrogen oxide pool]. Kyiv; 2009. Russian.

Kuriata AV, Syrenko OJu. [Insulin resistance and endothelial dysfunction in patients with arterial hyper­tension in combination with rheumatoid arthritis and their correction with L-arginine aspartate]. Therapy. Uk­rainskiy meditsinskiy vestnik. 2015;5:57-58. Russian.

Pertseva TA. [Features of treatment of patients with bronchial obstructive diseases in combination with diabetes and obesity]. Ukraїns'kiy pul'monologіchniy zhurnal. 2017;2:59. Russian.

[Order of the Ministry of Health ofUkraineN 1118 of 21.12.2012 "On Approval and Implementation of Medical-Technological Documents for the Stan­dardization of Medical Aid in Type 2 Diabetes"]. [In­ternet]. Ministry of Health ofUkraine; 2012. Available from: http://old.moz.gov.ua/ua/portal/­dn_20121221_1118.html

[Order of the Ministry of Health ofUkraineN 868 of 10.08.2013 "On Approval and Implementation of Medical-Technical Documents on Standardization of Medical Aid in Bronchial Asthma"]. [Internet]. Ministry of Health ofUkraine; 2013. Available from: http://old.moz.gov.ua/ua/portal/dn_20131008_0868.html

Feshchenko JuI. [Asthma, chronic obstructive pulmonary disease: promising global strategy of mana­gement, advanced diagnostic techniques, modern ap­proaches to therapy]. Astma ta alergіya. 2015;4:36-42. Ukranian.

Al-Shawwa B, Al-Huniti NH, DeMattia L, Ge­rshan W. Asthma and insulin resistance in morbidly obese children and adolescents. J Asthma. 2007;44(6):469-73.

Pereira ED, Cavalcante AG, Pereira EN, Lucas P, Holanda MA. Asthma control and quality of life in pa­tients with moderate or severe asthma. J Bras Pneumol. 2011;37(6):705-11.

Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: From bronchoconstriction to air­ways inflammation and remodeling. Am J Res­pirCritCa­reMed. 2000;161(5):1720-45.

Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636-45

Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine. EvidBasedMed. 2010;15:165-6.

Global strategy for asthma management and prevention.Bethesda: National Institutes of Health Na­tional Heart & Lung and Blood Institute. 2017;159.

Thuesen BH, Husemoen LLN, Hersoug LG, Pi­singer C, Linneberg A. Insulin resistance as a predictor of incident asthma-like symptoms in adults. ClinExp Al­lergy. 2009;39(5):700-7.

Juel CT-B, Ulrik CS. Obesity and asthma: impact on severity, asthma control, and response to therapy. Respir Care. 2013;58(5):867-73.

Rashid Q, Klein R. Tiotropium in the treatment of patients with asthma. South Med J. 2014;107(5):330-7.

Suissa S, Kezouh A, Ernst P. Inhaled corti­cos­teroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-6.

Tesse R, Schieck M, Kabesch M. Asthma and endocrine disorders: Shared mechanisms and genetic pleiotropy. MolCellEndocrinol. 2011;333(2):103-11.

Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. N Engl J Med. 2012;367(13):1198-207.


GOST Style Citations


  1. Баркаган З.С. Диагностика и контролируемая терапия нарушений гомеостаза / З.С. Баркаган, А.П. Момот. – Москва: Ньюдиамед, 2008. – 292 с.
  2. Верткин А.Л. Коморбидность – новая пато­логия. Технология ее профилактики и лечения / А.Л. Верткин, Н.О. Ховасова // Архив внутренней меди­цины. – 2013. – № 4. – С. 68-72.
  3. Катеренчук І.П. Оптимізація корекції ендоте­ліальної дисфункції у пацієнтів з метаболічним синд­ромом у практиці сімейного лікаря / І.П. Катеренчук // Ліки України. – 2014. – № 7/8. – С. 43-46.
  4. Ковалева О.М. Диагностика эндотелиальной функции-оценка вазоактивного пула оксида азота / О.М. Ковалева, Т.В. Горбач, Г.В. Демиденко. – Киев, 2009. – 19 с.
  5. Курята А.В. Инсулинорезистентность и эндо­телиальная дисфункция у больных с артериальной гипертензией в сочетании с ревматоидным артритом и их коррекция L-аргинина аспартатом / А.В. Курята, О.Ю. Сиренко // Therapia = Укр. мед. вестник. – 2015. – № 5. – С. 57-58.
  6. Перцева Т.А. Особенности лечения пациентов с бронхообструктивными заболеваниями в сочетании с сахарным диабетом и ожирением / Т.А. Перцева // Укр. пульмонол. журнал. – 2017. – № 2. – С. 59.
  7. Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при цукровому діабеті 2 типу: Наказ МОЗ України № 1118 від 21.12.2012 р. [Eлектронний ресурс] / МОЗ України. – Режим доступу: http://old.moz.gov.ua/ua/portal/dn_20121221_1118.html
  8. Про затвердження та впровадження медико-технічних документів зі стандартизації медичної до­помоги при бронхіальній астмі: Наказ МОЗ України № 868 від 08.10.2013 р. [Eлектронний ресурс] / МОЗ України. – Режим доступу: http://old.moz.gov.ua/­ua/portal/dn_20131008_0868.html
  9. Фещенко Ю.І. Бронхіальна астма, хронічне обструктивне захворювання легень: перспективна глобальна стратегія ведення, новітні методики діагностики, сучасні підходи до терапії / Ю.І. Фе­щенко // Астма та алергія. – 2015. – № 4. – С. 36-42.
  10. Asthma and insulin resistance in morbidly obese children and adolescents / B.A. Al-Shawwa, N.H. Al-Huniti, L. DeMattia, W. Gershan // The Journal of Asth­ma: official journal of the Association for the Care of Asthma. – 2007. – Vol. 44, N 6. – P. 469-473. doi: 10.1080/02770900701423597
  11. Pereira E.D.B. Asthma control and quality of life in patients with moderate or severe asthma / E.D.B. Pe­reira, A.G. de M. Cavalcante, E.N.S. Pereira [et al.] // J. Brasileiro de Pneumologia:publicaçãooficial da SociedadeBrasileira de Pneumologia e Tisiologia. – Vol. 37, N 6. – P. 705-711.
  12. Asthma: from bronchoconstriction to airways in­flam­mation and remodeling / J. Bousquet, P.K. Jeffery, W.W. Busse [et al.]. – 2000. doi: 10.1164/ajrccm.161.5.9903102
  13. Barnes P.J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease / P.J. Barnes // J. Allergy Clin. Immunol. – 2013. – Vol. 131, N 3. – P. 636-645. doi: 10.1016/j.jaci.2012.12.1564
  14. Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine / D. Campbell-Scherer // Evi­dence-Based Medicine. – 2010. – Vol. 15, N 6. – P. 165-166. doi: 10.1136/ebm1154
  15. Global strategy for asthma management and pre­vention / National Institutes of Health: National Heart, Lung and Blood Institute. –Bethesda, 2017. – 159 p.
  16. Insulin resistance as a predictor of incident asth­ma-like symptoms in adults / B.H. Thuesen, L.L.N. Hu­semoen, L.G. Hersoug [et al.] // Clinical and Expe­rimental Allergy. – 2009. = Vol. 39, No. 5. – P. 700-707. doi: 10.1111/j.1365-2222.2008.03197.x
  17. Juel C.T.-B. Obesity and asthma: impact on se­verity, asthma control, and response to therapy / C.T.‑B. Juel, C.S. Ulrik // Resp. Care. – 2013. – Vol. 58, N 5. – P. 867-873. doi: 10.4187/respcare.02202
  18. Rashid Q. Tiotropium in the treatment of patients with asthma / Q. Rashid, R. Klein. – 2014. doi: 10.1097/SMJ.0000000000000108
  19. Suissa S. Inhaled corticosteroids and the risks of diabetes onset and progression /S. Suissa, A. Kezouh, P. Ernst // Am. J. Med. – 2010. – Vol. 123, N 11. – P. 1001-1006. doi: 10.1016/j.amjmed.2010.06.019
  20. Tesse R. Asthma and endocrine disorders: shared me­chanisms and genetic pleiotropy / R. Tesse, M. Schieck, M. Kabesch. – 2011. doi: 10.1016/j.mce.2010.11.032
  21. Tiotropium in asthma poorly controlled with standard combination therapy / H.A.M. Kerstjens, M. En­gel, R. Dahl [et al.] // New Engl. J. Med. – 2012. – Vol. 367, N 13. – P. 1198-1207. doi: 10.1056/NEJMoa1208606




DOI: https://doi.org/10.26641/2307-0404.2018.1(part1).127209

Refbacks

  • There are currently no refbacks.